Melanoma

Cancer Forum

Volumn 37, Issue 1, 2013, Pages 65-66

  Thompson, John F ^a   Menzies, Alexander M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; DACARBAZINE; IPILIMUMAB; TRAMETINIB; VEMURAFENIB;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CUTANEOUS MELANOMA; DISEASE MANAGEMENT; DRUG WITHDRAWAL; EPIDEMIOLOGY; HEALTH CARE QUALITY; HUMAN; IMMUNOREGULATION; LYMPH NODE DISSECTION; MELANOMA; METASTATIC MELANOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE; SURVIVAL RATE;

EID: 84879374576     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Thompson JF, Shaw HM, Stretch JR, McCarthy WH, Milton GW. The Sydney Melanoma Unit - a multidisciplinary melanoma treatment center. Surg Clin North Am. 2003;83(2):431-51. (Pubitemid 36519198)
2. Lancaster HO, Nelson J. Sunlight as a cause of melanoma; a clinical survey. Med J Aust. 1957;44(14):452-6.
3. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. The Lancet. 2005;365(9460):687-701. (Pubitemid 40260892)
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206.
5. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23):2912-8.
6. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-9.
7. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-17. (Pubitemid 44465459)
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
9. Hauschild A, Grob JJ, Demidov LV, Jourary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2012;380(9839):358-65.
10. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med. 2012: [epub before print].
11. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med. 2012;367(18):1694-703.
12. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haann JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
13. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med. 2011;364(26):2517-26.